Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vestipitant versus ondansetron for breakthrough postoperative nausea and vomiting after failed ondansetron prophylaxis
2011-005216-28Phase 2Terminated
- Sponsor
- GSK
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of vestipitant in postoperative nausea and vomiting (PONV) (6 arms), sponsored by GSK. Primary endpoint: Complete Response after study drug for breakthrough postoperative nausea and vomiting. Started Jan 2012; status: terminated.
02
Drugs
vestipitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2011-005216-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005216-28.